PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer
Status:
Terminated
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the efficacy of the combination consisting of
gemcitabine/cisplatin and panitumumab in patients with urothelial carcinoma and wild-type
HRAS (non-mutated status). The progression-free survival rate at 12 months will be compared
to expectations derived from historical data, which are verified by a randomised control
group without the antibody.
Phase:
Phase 2
Details
Lead Sponsor:
WiSP Wissenschaftlicher Service Pharma GmbH
Collaborators:
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH